178 related articles for article (PubMed ID: 16722662)
1. Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.
Del Gatto A; Zaccaro L; Grieco P; Novellino E; Zannetti A; Del Vecchio S; Iommelli F; Salvatore M; Pedone C; Saviano M
J Med Chem; 2006 Jun; 49(11):3416-20. PubMed ID: 16722662
[TBL] [Abstract][Full Text] [Related]
2. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
4. A Combined NMR and Computational Approach to Determine the RGDechi-hCit-αv β3 Integrin Recognition Mode in Isolated Cell Membranes.
Farina B; de Paola I; Russo L; Capasso D; Liguoro A; Gatto AD; Saviano M; Pedone PV; Di Gaetano S; Malgieri G; Zaccaro L; Fattorusso R
Chemistry; 2016 Jan; 22(2):681-93. PubMed ID: 26548575
[TBL] [Abstract][Full Text] [Related]
5. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids.
Belvisi L; Bernardi A; Colombo M; Manzoni L; Potenza D; Scolastico C; Giannini G; Marcellini M; Riccioni T; Castorina M; LoGiudice P; Pisano C
Bioorg Med Chem; 2006 Jan; 14(1):169-80. PubMed ID: 16214345
[TBL] [Abstract][Full Text] [Related]
6. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells.
Maubant S; Saint-Dizier D; Boutillon M; Perron-Sierra F; Casara PJ; Hickman JA; Tucker GC; Van Obberghen-Schilling E
Blood; 2006 Nov; 108(9):3035-44. PubMed ID: 16835373
[TBL] [Abstract][Full Text] [Related]
7. Probing for integrin alpha v beta3 binding of RGD peptides using fluorescence polarization.
Wang W; Wu Q; Pasuelo M; McMurray JS; Li C
Bioconjug Chem; 2005; 16(3):729-34. PubMed ID: 15898744
[TBL] [Abstract][Full Text] [Related]
8. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
[TBL] [Abstract][Full Text] [Related]
9. Bifunctional ligands that target cells displaying the alpha v beta3 integrin.
Owen RM; Carlson CB; Xu J; Mowery P; Fasella E; Kiessling LL
Chembiochem; 2007 Jan; 8(1):68-82. PubMed ID: 17154219
[TBL] [Abstract][Full Text] [Related]
10. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part III: synthesis of potent antagonists with alpha(v)beta3/alpha(IIb)beta3 dual activity and improved water solubility.
Ishikawa M; Hiraiwa Y; Kubota D; Tsushima M; Watanabe T; Murakami S; Ouchi S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2131-50. PubMed ID: 16307881
[TBL] [Abstract][Full Text] [Related]
11. New potent and selective αvβ
Wu Z; Cheng X; Hong H; Zhao X; Zhou Z
Bioorg Med Chem Lett; 2017 May; 27(9):1911-1913. PubMed ID: 28351594
[TBL] [Abstract][Full Text] [Related]
12. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins.
Sung V; Stubbs JT; Fisher L; Aaron AD; Thompson EW
J Cell Physiol; 1998 Sep; 176(3):482-94. PubMed ID: 9699501
[TBL] [Abstract][Full Text] [Related]
13. Involvement of alpha(v)beta3 integrin-like receptor and glycosaminoglycans in Candida albicans germ tube adhesion to vitronectin and to a human endothelial cell line.
Santoni G; Spreghini E; Lucciarini R; Amantini C; Piccoli M
Microb Pathog; 2001 Oct; 31(4):159-72. PubMed ID: 11562169
[TBL] [Abstract][Full Text] [Related]
14. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
[TBL] [Abstract][Full Text] [Related]
15. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
Kubota D; Ishikawa M; Yamamoto M; Murakami S; Hachisu M; Katano K; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2089-108. PubMed ID: 16309911
[TBL] [Abstract][Full Text] [Related]
16. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
[TBL] [Abstract][Full Text] [Related]
17. Non-cytotoxic cobra cardiotoxin A5 binds to alpha(v)beta3 integrin and inhibits bone resorption. Identification of cardiotoxins as non-RGD integrin-binding proteins of the Ly-6 family.
Wu PL; Lee SC; Chuang CC; Mori S; Akakura N; Wu WG; Takada Y
J Biol Chem; 2006 Mar; 281(12):7937-45. PubMed ID: 16407244
[TBL] [Abstract][Full Text] [Related]
18. Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
Boys ML; Schretzman LA; Chandrakumar NS; Tollefson MB; Mohler SB; Downs VL; Penning TD; Russell MA; Wendt JA; Chen BB; Stenmark HG; Wu H; Spangler DP; Clare M; Desai BN; Khanna IK; Nguyen MN; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Steininger CN; Westlin M; Westlin W; Yu YX; Wang Y; Dalton CR; Norring SA
Bioorg Med Chem Lett; 2006 Feb; 16(4):839-44. PubMed ID: 16298127
[TBL] [Abstract][Full Text] [Related]
19. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor.
Kumar CC; Nie H; Rogers CP; Malkowski M; Maxwell E; Catino JJ; Armstrong L
J Pharmacol Exp Ther; 1997 Nov; 283(2):843-53. PubMed ID: 9353406
[TBL] [Abstract][Full Text] [Related]
20. Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.
Zanardi F; Burreddu P; Rassu G; Auzzas L; Battistini L; Curti C; Sartori A; Nicastro G; Menchi G; Cini N; Bottoncetti A; Raspanti S; Casiraghi G
J Med Chem; 2008 Mar; 51(6):1771-82. PubMed ID: 18303826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
